Mogrify
Biotech company pioneering the field of in vivo reprogramming therapies.
Mogrify has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion and the maintenance of cell identity.
Visit website: https://mogrify.co.uk/
mogrify-developing-next-generation-cell-therapies
Details last updated 24-Nov-2020
Mogrify News
Mogrify boosts series A to $46m to accelerate cellular reprogramming therapies
Longevity Technology - 03-Oct-2023
Technology could revolutionise the treatment of degenerative diseases
Read more...Mogrify and Astellas collaborate on novel gene therapy for hearing loss
Labiotech - 17-Nov-2022
Breakthrough approach to regenerate new cochlear hair cells that enable hearing
Read more...Advances in stem cell cures by new biotech startups
GEN News - 03-Nov-2020
New generation companies develop novel cell therapies using stem cells
Read more...